Strengths

Current ratio of 2.37 and quick ratio of 1.60 indicate better near-term liquidity than more levered peers, supporting operating flexibility despite weak profitability.

Debt-to-equity of 0.57 is moderate for a medtech company, leaving balance-sheet risk below highly levered peers and preserving some financing capacity.

The company’s cash conversion cycle is long at 332 days, but its liquidity cushion partially offsets working-capital drag better than peers with tighter short-term funding.

ROIC of -2.9% is weak, yet the absence of extreme leverage suggests structural solvency is less impaired than peers with similar returns but heavier debt loads.

Weaknesses

ROIC of -2.9% shows capital is not earning its cost, leaving ZIMV structurally behind profitable peers in long-term value creation.

Net debt to EBITDA of 6.35 signals elevated leverage versus stronger peers, constraining strategic flexibility and amplifying earnings sensitivity to execution.

Cash conversion cycle of 332 days is very long, tying up working capital more than peers and pressuring cash generation and reinvestment capacity.

The combination of weak returns and meaningful leverage leaves ZIMV less resilient than peers with stronger margins, faster cash conversion, and lower debt.

Opportunities

If working capital is normalized, the 332-day cash conversion cycle offers more upside than peers with already efficient cycles, improving cash generation.

Liquidity ratios above 1.5 provide room to fund operational improvements faster than constrained peers, supporting gradual competitive repair.

Relative leverage is manageable enough to allow refinancing or deleveraging actions that could narrow the gap versus more indebted peers.

Any improvement in capital efficiency would have outsized impact because current returns are negative, creating more upside than for already efficient peers.

Threats

Persistently negative ROIC leaves ZIMV vulnerable to peers with stronger returns that can reinvest more aggressively and compound market share.

High net debt to EBITDA increases downside risk versus less levered peers if demand softens or execution slips, limiting strategic optionality.

A 332-day cash conversion cycle heightens exposure to inventory and receivables shocks relative to peers with faster cash realization.

If competitive intensity rises, peers with better profitability and balance-sheet strength can absorb pricing pressure more easily than ZIMV.

Overall Score

ZIMV’s structural positioning versus peers is weak because negative returns and elevated leverage outweigh its moderate liquidity cushion and leave limited durable advantage.